Literature DB >> 2550600

ras oncogene p21 expression in hepatocellular carcinoma.

J Jagirdar1, A Nonomura, J Patil, A Thor, F Paronetto.   

Abstract

Aberrant proto-oncogene expression has been implicated in hepatic cell proliferation, transformation and carcinogenesis using a rat model. To investigate the role of ras p21 product expression in human hepatocellular carcinoma (HCC), we have localized ras p21 in formalin fixed, paraffin-embedded normal and abnormal livers utilizing the avidin-biotin peroxidase method and a monoclonal antibody to ras-gene product p21. A semi-quantitative estimate of p21 expression was performed by serial dilutions of primary antibody. While low dilutions of anti-p21 stained normal hepatocytes, higher dilutions failed to react with normal hepatocytes and these dilutions were used for assessment of p21 enhancement. Increased p21 expression of ras oncogene in HCC occurs in fibrolamellar carcinomas and other better differentiated HCC. Tumor dedifferentiation is associated with an attenuation of p21 expression. Liver adjacent to HCC exhibits p21 enhancement, in contrast to liver surrounding metastatic carcinoma, suggesting increased p21 expression in HCC induction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550600

Source DB:  PubMed          Journal:  J Exp Pathol        ISSN: 0730-8485


  7 in total

Review 1.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Authors:  Roberta Schmieder; Florian Puehler; Roland Neuhaus; Maria Kissel; Alex A Adjei; Jeffrey N Miner; Dominik Mumberg; Karl Ziegelbauer; Arne Scholz
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 3.  New insights in hepatocellular carcinoma: from bench to bedside.

Authors:  Samuele De Minicis; Marco Marzioni; Antonio Benedetti; Gianluca Svegliati-Baroni
Journal:  Ann Transl Med       Date:  2013-07

4.  Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras.

Authors:  Nahed Baddour; Ebtehal Farrag; Ahmed Zeid; Essam Bedewy; Yousry Taher
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

Review 5.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

6.  Molecular mechanisms underlying hepatocellular carcinoma.

Authors:  Philippe Merle; Christian Trepo
Journal:  Viruses       Date:  2009-11-09       Impact factor: 5.048

Review 7.  MicroRNA involvement in hepatocellular carcinoma.

Authors:  Laura Gramantieri; Francesca Fornari; Elisa Callegari; Silvia Sabbioni; Giovanni Lanza; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.